Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7035672 | 0.78 | TSHR (0.44) | GPR35CA2CA1ALDH1A1KDM4E | |
| SCHEMBL540381 | 0.77 | MAPT (0.45) | GPR35ALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL9455823 | 0.76 | VCAM1 (0.44) | GPR35ALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL928995 | 0.74 | MAPT (0.46) | GPR35ALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL5258907 | 0.74 | ESPL1 (0.47) | GPR35ALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL9915413 | 0.73 | HCAR2 (0.35) | ALDH1A1KDM4EMAPTTSHR | |
| SCHEMBL7017758 | 0.72 | ALDH1A1 (0.51) | ALDH1A1KDM4EMAPTNPC1RAB9A | |
| SCHEMBL10664976 | 0.71 | ALDH1A1 (0.44) | ALDH1A1SIRT6KDM4EMAPTNPC1 | |
| SCHEMBL11835122 | 0.70 | GPR35 (0.60) | GPR35CA12CA2CA9CA1 | |
| SCHEMBL62337 | 0.70 | GPR35 (0.54) | GPR35CA12CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615515-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-110914241-B | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-110914242-B | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| CN-110914241-A | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-110914242-A | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3615514-A2 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | Aviara Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-3615515-A2 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | Aviara Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20190225602-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | US | disclosed |
| EP-1039907-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6245769-B1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders | DUPONT PHARMACEUTICALS COMPANY | 2001-06-12 | — | — | US | disclosed |
| EP-1039907-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6107301-A | PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| US-6107300-A | CORTICOTROPIN RELEASING FACTOR ANTAGONIST; PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS (US) | 2000-08-22 | — | — | US | disclosed |
| US-6004976-A | ADMINISTERING IMIDAZO(4,5-C)PYRIDIN-2,4-DIONE DERIVATIVES AS ANTICOAGULANTS | MERCK & CO., INC. (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0934064-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1999027930-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1999-06-10 | — | — | WO | disclosed |
| US-5869487-A | HIGH SELECTIVITY FOR THROMBIN; TREATING UNSTABLE ANGINA, MYOCARDIAL INFARCTION, ATRIAL FIBRILLATION, DEEP VEIN THROMBOSIS AND OTHER DISEASES | MERCK & CO., INC. (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998017274-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225602-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGA4, ITGB3, ITGB4 | GPR35 313/4885CA12 2338/4885CA2 1203/4885 |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | ITGB3, ITGA1, ITGB5 | GPR35 178/4885CA12 2557/4885CA2 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.